RECKITT BENCKISER GROUP PLC
Voting Rights and Capital
In conformity with the Disclosure Guidance and Transparency Rules (DTR 5.6.1), as at 30 April 2019, Reckitt Benckiser Group plc:
· has 736,535,179 issued ordinary shares of 10p each admitted to trading. Each ordinary share carries the right to one vote in relation to all circumstances at general meetings of Reckitt Benckiser Group plc;
· holds 28,659,103 ordinary shares in treasury. The voting rights of treasury shares are automatically suspended; and
· accordingly, has total voting rights of 707,876,076.
The total voting rights figure (707,876,076) may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Reckitt Benckiser Group plc under the FCA's Disclosure Guidance and Transparency Rules.
Deputy Company Secretary
Reckitt Benckiser Group plc
103-105 Bath Road, Slough SL1 3UH
Registered in England and Wales, No. 6270876
Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108
RB is the global leading consumer health, hygiene and home company. Driven by a purpose of providing innovative solutions for healthier lives and happier homes, RB has operations in over 60 countries. From the foundations of wellness and infant nutrition, to the fundamentals of a hygienic home, its global brands help people live healthier, happier lives.
RB has world leading Powerbrands which include household names such as Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Woolite and Air Wick.
RB's unique culture is at the heart of its success. Its drive to achieve, passion to outperform and commitment to quality and scientific excellence is manifested in the work of over 40,000 employees worldwide.
For more information visit www.rb.com
*RB is the trading name of the Reckitt Benckiser group of companies
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.